ERBB2 and breast cancer: Given that luminal A breast cancers are mostly recognized for having low immunogenic potential compared to luminal B, basal (including TNBC), and HER2-positive breast cancer subtypes, prespecified subgroup analyses investigated the value of sTILs in IHC-defined luminal A versus non-luminal A for prognostication and predicting benefit from RNI.